25I-NB3OMe

25I-NB3OMe (2C-I-NB3OMe, NB3OMe-2C-I) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1][2]

25I-NB3OMe
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(3-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H22INO3
Molar mass427.282 g·mol−1
3D model (JSmol)
SMILES
  • COC1=CC=CC(=C1)CNCCC2=CC(=C(C=C2OC)I)OC
InChI
  • InChI=1S/C18H22INO3/c1-21-15-6-4-5-13(9-15)12-20-8-7-14-10-18(23-3)16(19)11-17(14)22-2/h4-6,9-11,20H,7-8,12H2,1-3H3
  • Key:CJTZKPLDKCBUAF-UHFFFAOYSA-N

Legality

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[3]

United States

25I-NB3OMe is not a controlled substance, but is a positional isomer of 25I-NBOMe and thus may be considered a Schedule I drug under the Federal Analogue Act, meaning that it would be subject to the same penalties for possession, distribution, and manufacture as 25I-NBOMe.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.